Navigation Links
Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
Date:8/20/2007

inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical non-oncology programs: MGCD290, an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; and a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of product candidates to demonstrate safety and efficacy in clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and comp
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... ( www.aapc.com ) announced its 2012 medical coding books ... previous year. Prices have been reduced more than 55 percent over ... reduction was to benefit our more than 100,000 members, non-members of ... Starynskaya, coding books department manager for of AAPC. ...
... (NASDAQ: ITMN ) today announced that it will ... open of the U.S. markets on Thursday, April 28, 2011. ... InterMune at 8:30 a.m. Eastern time that same day. ... 706-643-9223 (international), conference ID# 62213806.  To access the webcast, please ...
... Eigen is the proud recipient of two grant awards ... U.S. Department of Health & Human Services. QTDP tax credits ... (IRC), enacted as part of the Patient Protection and Affordable ... $244,000 award for each grant awarded in October, 2010, and ...
Cached Biology Technology:AAPC Lowers Prices on Medical Coding Books, Again 2Eigen Receives Two Grant Awards from U.S. Department of Health & Human Services 2
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... select partners? Darwin,s initial idea that the fittest males ... likely to secure partners has represented a cornerstone of evolutionary ... 1871. Darwin proposed that secondary sexual characteristics enabled females ... best for every female. This male would be the ...
... three percent (n=181) of patients in the study cohort ... their arthritis developed a first cancer within nine years ... of arthritis. The nine year follow-up study conducted ... ((RR)=1.03 (95%confidence interval 0.82-1.30)) was not increased in patients ...
... Scientists from the University of Warwick have discovered ... be ,ultra-bad, leading to increased risk of heart disease. ... heart disease particularly in people with type 2 diabetes ... British Heart Foundation (BHF), found that ,ultrabad, cholesterol, called ...
Cached Biology News:The importance of 'inner values' -- female sparrows test the genetic make-up of their mates 2Arthritis patients taking newer treatments do not have an overall increased cancer risk 2Super-sticky 'ultra-bad' cholesterol revealed in people at high risk of heart disease 2
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
Complement factor B (human)...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... 10 Capillary Electrophoresis Running Buffer was designed ... throughput demands of todays sequencing labs. As ... TBE to the gel-based sequencing community Sigma ... capacity to meet your buffer needs. Scientists ...
Biology Products: